Guggenheim Says Bausch Health Companies (BHC) Sell-Off 'Overdone'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St set for higher open but weekly losses loom
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Cowen Defends Bausch Health Companies (BHC); 'Add Here'
February 19, 2020 11:37 AM ESTCowen analyst Ken Cacciatore reiterated an Outperform rating and $40.00 price target on Bausch Health Companies (NYSE: BHC), saying there is no change to the thesis and investors should add here.
The analyst commented, "Q4 revs were slightly above the Street, while earnings... More
Bausch Health Co. Inc. (BHC) Posts Q4 Adjusted EBITDA of $898 Million, Revs Beat
February 19, 2020 7:02 AM ESTBausch Health Co. Inc. (NYSE: BHC) reported Q4 Adjusted EBITDA of $898 Million. Revenue for the quarter came in at $2.28 billion versus the consensus estimate of $2.2 billion.
GUIDANCE:
Bausch Health Co. Inc. sees FY2020 revenue of $8.65-8.85 billion, versus the consensus of... More
